Report : Middle East and Africa Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Bioreactor, Lyophilization, Electrospinning, Control flow Centrifugation, Ultrasonic Lysis, Genome Editing Technology, Cell Immortalization Technology, and Viral Vector Technology); Cell Type (Stem Cell, Immune Cell, Human Embryonic Stem Cell, Pluripotent Stem Cell, and Hematopoietic Stem Cells), Indication (Cardiovascular Disease (CVD), Oncology, Wound Healing, Orthopaedic, and Others); End User (Hospitals and Clinics, Diagnostic Centres, Regenerative Medicine Centres, and Academic and Research Institute)
Bioreactor Segment has the Largest Share of Technology in the Middle East and Africa Cell Therapy Bioprocessing Market during 2021–2028
According to a new market research study on “Middle East and Africa Cell Therapy Bioprocessing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology, Cell Type, Indication, and End User” is expected to reach US$ 832.5 million by 2028 from US$ 393.7 million in 2021. The market is estimated to grow at a CAGR of 11.3% from 2021 to 2028. The report provides trends prevailing in the Middle East and Africa Cell therapy bioprocessing market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the challenges such as high cost of product, regulatory challenges, and logistics challenges.
Countries such as UAE, and Saudi Arabia have also registered a significant number of positive patients. This region is developing in terms of the medical industry. The countries in this region are highly dependent on medical devices and pharmaceutical products. Therefore, countries have faced several challenges for their requirements. Initial phase of lockdown in various countries has affected the supply of many bioprocessing in these regions. However, the lockdown has affected the supply chain of various companies in these regions. Therefore, many organizations are collaborating with others to overcome this pandemic by using cell therapies for the treatment of COVID 19. For instance, in May 2020, Prince of Abu Dhabi has announced to cover all costs of Stem cell therapy of COVID 19 patients. Moreover, United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC) has entered into collaboration agreement with Pluristem Therapeutics Inc. to develop cell therapies and regenerative medicines for the treatment of COVID-19. This cell therapy has been named UAECell19, which has been used to treat approximately 5000 COVID-19 affected people successfully. Such initiatives will bring significant growth for cell therapy market in long run.
The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, in 2020, the bioreactor segment accounted for the cell therapy bioprocessing market's most significant market share. The segment's growth is expected due to its utilization for making cells and scaling up the volume for cellular products. Bioreactors are the primary equipment required during the cell therapy bioprocessing thus are expected to continue their dominancy during the forecast period. However, the genome-editing technology segment is expected to grow at the fastest CAGR. Genome editing technology is widely used for targeting and designing the cellular and genes for cell therapies.
Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc are among the leading companies in the Middle East and Africa cell therapy bioprocessing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2021, Sartorius Partners with RoosterBio. The partnership seeks to drive the scale-up of hMSC production for regenerative medicine by exploiting both companies' best-in-class solutions to dramatically minimise process development efforts, industrialise the supply chain, and accelerate the growth and commercialization of game-changing cell-based regenerative cures.
The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, the Cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electrospinning, control flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Based on cell type, the cell therapy bioprocessing market is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, and hematopoietic stem cells. Based on indication, the cell therapy bioprocessing market is segmented into cardiovascular disease (cvd), oncology, wound healing, orthopaedic, and others. Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centres, regenerative medicine centres, and academic and research institute. Geographically, the cell therapy bioprocessing market is segmented into Middle East and Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East and Africa).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com